Moderna, Inc. $MRNA Shares Sold by HB Wealth Management LLC

HB Wealth Management LLC cut its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 8.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,281 shares of the company’s stock after selling 662 shares during the period. HB Wealth Management LLC’s holdings in Moderna were worth $201,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. S Bank Fund Management Ltd bought a new stake in Moderna during the first quarter worth approximately $25,000. TD Private Client Wealth LLC raised its holdings in Moderna by 348.8% during the second quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock worth $26,000 after purchasing an additional 743 shares in the last quarter. SVB Wealth LLC bought a new stake in Moderna during the first quarter worth approximately $28,000. CX Institutional raised its holdings in Moderna by 1,129.8% during the second quarter. CX Institutional now owns 1,033 shares of the company’s stock worth $29,000 after purchasing an additional 949 shares in the last quarter. Finally, Costello Asset Management INC bought a new stake in Moderna during the first quarter worth approximately $30,000. Institutional investors own 75.33% of the company’s stock.

Moderna Trading Down 0.7%

Shares of NASDAQ:MRNA opened at $27.34 on Wednesday. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $59.73. The business has a fifty day simple moving average of $26.06 and a 200 day simple moving average of $27.30. The firm has a market cap of $10.68 billion, a price-to-earnings ratio of -3.63 and a beta of 2.01.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.99) by $0.86. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The business had revenue of $142.00 million during the quarter, compared to analyst estimates of $116.26 million. During the same period last year, the company earned ($3.33) earnings per share. Moderna’s quarterly revenue was down 41.1% compared to the same quarter last year. Moderna has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Moderna, Inc. will post -9.61 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Barclays dropped their target price on Moderna from $40.00 to $31.00 and set an “equal weight” rating on the stock in a report on Monday, August 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Moderna in a report on Saturday, September 27th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $32.00 price target on shares of Moderna in a report on Friday, August 1st. Bank of America dropped their price target on Moderna from $26.00 to $25.00 and set an “underperform” rating on the stock in a report on Tuesday, July 22nd. Finally, Citigroup began coverage on Moderna in a report on Friday, August 1st. They issued a “neutral” rating and a $40.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, fourteen have issued a Hold rating and five have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $41.81.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.